间充质基质细胞治疗急性呼吸窘迫综合征(REALIST):开放标签剂量递增1期试验及随机三盲分配隐藏安慰剂对照2期试验的结构化研究方案
REALIST试验研究一种符合药品生产质量管理规范(GMP)的CD362富集脐带来源间充质基质细胞产品(REALIST ORBCEL-C)治疗中重度急性呼吸窘迫综合征(ARDS)患者。1期为多中心开放标签剂量递增3+3设计先导试验,2期为多中心随机三盲分配隐藏安慰剂对照试验,纳入COVID-19所致ARDS及其他原因所致ARDS两个队列,每个队列计划招募60例患者。主要安全性结局为严重不良事件发生率,主要有效性结局为第7天氧合指数。
要点
- 1期采用3+3设计,单次输注REALIST ORBCEL-C 100×10^6、200×10^6或400×10^6细胞。
- 2期将患者按1:1随机分配至REALIST ORBCEL-C(400×10^6细胞或1期最大耐受剂量)或安慰剂。
- 2期设COVID-19所致ARDS及其他原因所致ARDS两个队列,每队列计划招募60例患者。
核心结论
- 本方案描述REALIST试验的1期剂量递增和2期随机对照设计,旨在评估REALIST ORBCEL-C在COVID-19所致ARDS及其他原因所致ARDS患者中的安全性和有效性。
研究设计与样本
- 1期为多中心开放标签剂量递增先导试验,采用3+3设计。
- 2期为多中心随机、三盲、分配隐藏、安慰剂对照试验,设COVID-19所致ARDS和其他原因所致ARDS两个队列,每队列计划招募60例患者,按1:1随机。
- 试验将按照CONSORT 2010声明报告。
主要发现
- 主要安全性结局为严重不良事件发生率。
- 主要有效性结局为第7天氧合指数。
关键数值与推荐
- 1期单次输注REALIST ORBCEL-C的剂量为100×10^6细胞、200×10^6细胞或400×10^6细胞。
- 2期单次输注REALIST ORBCEL-C的剂量为400×10^6细胞或1期最大耐受剂量。
- 2期每队列计划招募60例患者。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to immunomodulatory and reparative properties. This trial investigates a novel CD362 enriched umbilical cord derived MSC product (REALIST ORBCEL-C), produced to Good Manufacturing Practice standards, in patients with moderate to severe ARDS due to COVID-19 and ARDS due to other causes. METHODS: Phase 1 is a multicentre open-label dose-escalation pilot trial. Patients will receive a single infusion of REALIST ORBCEL-C (100 × 106 cells, 200 × 106 cells or 400 × 106 cells) in a 3 + 3 design. Phase 2 is a multicentre randomised, triple blind, allocation concealed placebo-controlled trial. Two cohorts of patients, with ARDS due to COVID-19 or ARDS due to other causes, will be recruited and randomised 1:1 to receive either a single infusion of REALIST ORBCEL-C (400 × 106 cells or maximal tolerated dose in phase 1) or placebo. Planned recruitment to each cohort is 60 patients. The primary safety outcome is the incidence of serious adverse events. The primary efficacy outcome is oxygenation index at day 7. The trial will be reported according to the Consolidated Standards for Reporting Trials (CONSORT 2010) statement. DISCUSSION: The development and manufacture of an advanced therapy medicinal product to Good Manufacturing Practice standards within NHS infrastructure are discussed, including challenges encountered during the early stages of trial set up. The rationale to include a separate cohort of patients with ARDS due to COVID-19 in phase 2 of the trial is outlined. TRIAL REGISTRATION: ClinicalTrials.gov NCT03042143. Registered on 3 February 2017. EudraCT Number 2017-000584-33.
引用
- Gorman E, Shankar-Hari M, Hopkins P, et al. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. Trials. 2022. PMID: 35562778. doi:10.1186/s13063-022-06220-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。